Omalizumab

SAN DIEGO — Approximately 45,000 patients have begun using omalizumab for food allergy in the year since its approval by the FDA, Ahmar Iqbal, MD, therapeutic area lead for respiratory and influenza at Genentech, told Healio here.

SAN DIEGO — Multiple risk factors were associated with denials and longer wait times for biologic treatment in moderate to severe asthma, as well as with discontinuations, according to a series of posters presented here.

The FDA approved Celltrion’s omalizumab biosimilar, Omlyclo, for the treatment of multiple conditions including asthma and food allergy, according to an agency press release.

SAN DIEGO — Patients with multiple food allergies introduced allergens into their diets after using omalizumab, researchers reported at the 2025 American Academy of Allergy, Asthma & Immunology/World Allergy Organization Joint Congress.

SAN DIEGO — Across six asthma biologics, adherence differed by the therapy given and was often low or irregular based on three adherence measures, according to a presentation here.

SAN DIEGO — Patients with three different food allergies who used omalizumab experienced better outcomes than patients who used multi-food oral immunotherapy, driven by lower rates of adverse events, according to an abstract presented here.

As we approach the first anniversary of omalizumab’s approval for food allergy, its use is “definitely going to grow,” Robert A. Wood, MD, FAAAAI, professor of pediatrics, Johns Hopkins University School of Medicine, told Healio.

BOSTON — Patients with obesity and asthma may see reductions in exacerbations with biologic treatment, according to a presentation at the CHEST Annual Meeting.

BOSTON — Asthma control during pregnancy lowers the risk for complications, according to a presentation at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting.

BOSTON — The use of biologics to treat asthma during pregnancy “is very likely safe,” but the choice should follow shared decision-making, S. Shahzad Mustafa, MD, said during his presentation at the CHEST Annual Meeting.